

ALDA PHARMACEUTICALS CORP.

**635 Columbia Street
New Westminster, British Columbia V3M 1A7
Tel: (604) 521-8300 Fax: (604) 521-8322**

NEWS RELEASE

TSX-V SYMBOL: APH

May 6, 2008

ALDA to request human trials for T³6[®] skin antiseptic

Vancouver, BC - ALDA Pharmaceuticals Corp. (APH:TSX-V, "ALDA") announces that it has received the final results from BioScience Laboratories, Inc. for the T³6[®] formulation ("T³6[®]") tested against 10 different types of viruses. Of these, 5 types were killed within the minimum 30-second time required by the FDA, including Herpes Types I and II and Influenza B. The remaining 5 types, including Polio and Hepatitis A, the hardest viruses, were killed within 1 to 3 minutes.

Successful completion of these tests allows ALDA to approach Health Canada with a Clinical Trial Application ("CTA") for testing of T³6[®] as a skin antiseptic for surgical use and for personal sanitation. Once the CTA has been approved by Health Canada, human trials can begin. ALDA can also request a "pre-IND" (pre-Investigational New Drug) meeting with the FDA for the same indications. This meeting will determine if any additional tests are required by the FDA before human trials can begin in the US.

Dr. Terrance Owen, President & CEO, states, "This is an important milestone for ALDA. Now that ALDA has successfully passed all of the initial microbial tests, we can advance to the next stage and request human trials for registration of T³6[®] as a skin antiseptic for institutional and consumer use. From our extensive toxicology studies, we know that T³6[®] is very safe, as well as being very effective. On this basis, we are hoping for a positive outcome from these meetings."

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection-control therapeutics derived from its patented T³6[®] technology. The company trades on the TSX Venture Exchange under the symbol APH.

Terrance G. Owen, Ph.D., MBA
President, CEO and Director
ALDA Pharmaceuticals Corp.
www.aldacorp.com

Distribution & Sales Contact
Peter Chen
(604) 521- 8300 Ext. 3
peter_chen@aldacorp.com

Investor Relations Contact
Scott Young
604-288-7222
syoung@freeformcom.com

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.